WO1999001567A3 - Methods and compositions for a deubiquitinating enzyme and variants thereof - Google Patents

Methods and compositions for a deubiquitinating enzyme and variants thereof Download PDF

Info

Publication number
WO1999001567A3
WO1999001567A3 PCT/US1998/013776 US9813776W WO9901567A3 WO 1999001567 A3 WO1999001567 A3 WO 1999001567A3 US 9813776 W US9813776 W US 9813776W WO 9901567 A3 WO9901567 A3 WO 9901567A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
methods
enzyme
compositions
deubiquitinating
Prior art date
Application number
PCT/US1998/013776
Other languages
French (fr)
Other versions
WO1999001567A2 (en
WO1999001567A9 (en
Inventor
Christopher P Hill
Keith D Wilkinson
Steven C Johnston
Christopher N Larsen
William J Cook
Original Assignee
Univ Utah
Univ Emory
Christopher P Hill
Keith D Wilkinson
Steven C Johnston
Christopher N Larsen
William J Cook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah, Univ Emory, Christopher P Hill, Keith D Wilkinson, Steven C Johnston, Christopher N Larsen, William J Cook filed Critical Univ Utah
Publication of WO1999001567A2 publication Critical patent/WO1999001567A2/en
Publication of WO1999001567A3 publication Critical patent/WO1999001567A3/en
Publication of WO1999001567A9 publication Critical patent/WO1999001567A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention relates to methods for the identification of candidate inhibitor substances that inhibit deubiquitinating activity based on the x-ray crystallographic structure of the active site of the enzyme. Changes in the properties of the enzyme are useful in identifying such substances. Also disclosed are variants of the enzyme that are useful in deubiquitinating proteins and small peptides.
PCT/US1998/013776 1997-07-01 1998-07-01 Methods and compositions for a deubiquitinating enzyme and variants thereof WO1999001567A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5143797P 1997-07-01 1997-07-01
US60/051,437 1997-07-01

Publications (3)

Publication Number Publication Date
WO1999001567A2 WO1999001567A2 (en) 1999-01-14
WO1999001567A3 true WO1999001567A3 (en) 1999-04-01
WO1999001567A9 WO1999001567A9 (en) 1999-05-14

Family

ID=21971318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013776 WO1999001567A2 (en) 1997-07-01 1998-07-01 Methods and compositions for a deubiquitinating enzyme and variants thereof

Country Status (1)

Country Link
WO (1) WO1999001567A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1297053A (en) * 1999-11-22 2001-05-30 上海博容基因开发有限公司 Polypeptide-human ubiquitin C-end hydrolase 28 and polynucleotide for coding said polypeptide
CN1315559A (en) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 Polypeptide-human obiqitin carboxylic acid terminal hydrolase 10 and polynucleotide for coding it
US20020133842A1 (en) * 2000-12-08 2002-09-19 Leviten Michael W. Transgenic mice containing deubiquitinated enzyme gene disruptions
WO2002052269A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2006251941B2 (en) 2005-05-27 2012-02-09 Onyx Therapeutics, Inc. Novel substrate for Rpn11 enzymatic activity
AU2012202284B2 (en) * 2005-05-27 2014-11-20 Onyx Therapeutics, Inc. Novel substrate for Rpn11 enzymatic activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585466A (en) * 1994-12-06 1996-12-17 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Crystals of serum albumin for use in genetic engineering and rational drug design
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585466A (en) * 1994-12-06 1996-12-17 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Crystals of serum albumin for use in genetic engineering and rational drug design
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LARSEN C. N., PRICE J. S., WILKINSON K. D.: "SUBSTRATE BINDING AND CATALYSIS BY UBIQUITIN C-TERMINAL HYDROLASES: IDENTIFICATION OF TWO ACTIVE SITE RESIDUES.", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 35., 1 May 1996 (1996-05-01), US, pages 6735 - 6744., XP002916369, ISSN: 0006-2960, DOI: 10.1021/bi960099f *

Also Published As

Publication number Publication date
WO1999001567A2 (en) 1999-01-14
WO1999001567A9 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
NZ520659A (en) Xylanase variants having altered sensitivity to xylanase inhibitors caused by mutations in the lid region
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
WO1996016172A3 (en) Modulators of anchoring protein function
EE200000488A (en) Phospholipase enzyme inhibitors and pharmaceutical compositions
AU7349198A (en) Nucleic acid probes for the detection and identification of fungi
IS5905A (en) Alzheimer's secretion
WO2001049098A3 (en) Alzheimer's disease secretase, app substrates therefor, and uses therefor
EE200000522A (en) Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity
ZA974542B (en) New amino acid derivatives and their use as thrombin inhibitors.
DK0495918T3 (en) Amino acid beta-lyase enzyme inhibitors as deodorants
DE69822307D1 (en) HUMAN ADAMTS-1 PROTEIN, GENE WHICH CODES THIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE IMMUNOLOGICAL DETERMINATION OF HUMAN ADAMTS-1 PROTEINS
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
ATE108205T1 (en) RECOMBINANT METHODS FOR THE PRODUCTION OF SERIN PROTEAS INHIBITORS, AND DNA SEQUENCES THEREFOR.
DK1025236T3 (en) Human checkpoint kinase, HCDS1, preparations and methods
CA2128711A1 (en) Trypsin inhibitors
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
WO1999001567A3 (en) Methods and compositions for a deubiquitinating enzyme and variants thereof
EP0614970A3 (en) Hydroxyphenylpyruvate-dioxygenase inhibitors and assay for the identification of the enzyme.
EP1080724A4 (en) Mtp activity-lowering compositions
AU6877998A (en) Dipeptide inhibitors of protein farnesyltransferase
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
ATE362768T1 (en) PRB2/P130 PEPTIDE INHIBITORS OF CDK2 KINASE ACTIVITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 6-163, DESCRIPTION, REPLACED BY NEW PAGES 6-170; PAGES 164-166, CLAIMS, REPLACED BY NEW PAGES171-173; PAGES 1/19-19/19, DRAWINGS, REPLACED BY NEW PAGES 1/19-19/19; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: KR

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999508763

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase